Cable Viewer

Currently released so far... 12476 / 251,287

### Browse latest releases

2010/11 2010/12 2011/01 2011/02 2011/03 2011/04 2011/05
2010/11/28 2010/11/29 2010/11/30
2010/12/01 2010/12/02 2010/12/03 2010/12/04 2010/12/05 2010/12/06 2010/12/07 2010/12/08 2010/12/09 2010/12/10 2010/12/11 2010/12/12 2010/12/13 2010/12/14 2010/12/15 2010/12/16 2010/12/17 2010/12/18 2010/12/19 2010/12/20 2010/12/21 2010/12/22 2010/12/23 2010/12/24 2010/12/25 2010/12/26 2010/12/27 2010/12/28 2010/12/29 2010/12/30
2011/01/01 2011/01/02 2011/01/04 2011/01/05 2011/01/07 2011/01/09 2011/01/10 2011/01/11 2011/01/12 2011/01/13 2011/01/14 2011/01/15 2011/01/16 2011/01/17 2011/01/18 2011/01/19 2011/01/20 2011/01/21 2011/01/22 2011/01/23 2011/01/24 2011/01/25 2011/01/26 2011/01/27 2011/01/28 2011/01/29 2011/01/30 2011/01/31
2011/02/01 2011/02/02 2011/02/03 2011/02/04 2011/02/05 2011/02/06 2011/02/07 2011/02/08 2011/02/09 2011/02/10 2011/02/11 2011/02/12 2011/02/13 2011/02/14 2011/02/15 2011/02/16 2011/02/17 2011/02/18 2011/02/19 2011/02/20 2011/02/21 2011/02/22 2011/02/23 2011/02/24 2011/02/25 2011/02/26 2011/02/27 2011/02/28
2011/03/01 2011/03/02 2011/03/03 2011/03/04 2011/03/05 2011/03/06 2011/03/07 2011/03/08 2011/03/09 2011/03/10 2011/03/11 2011/03/13 2011/03/14 2011/03/15 2011/03/16 2011/03/17 2011/03/18 2011/03/19 2011/03/20 2011/03/21 2011/03/22 2011/03/23 2011/03/24 2011/03/25 2011/03/26 2011/03/27 2011/03/28 2011/03/29 2011/03/30 2011/03/31
2011/04/01 2011/04/02 2011/04/03 2011/04/04 2011/04/05 2011/04/06 2011/04/07 2011/04/08 2011/04/09 2011/04/10 2011/04/11 2011/04/12 2011/04/13 2011/04/14 2011/04/15 2011/04/16 2011/04/17 2011/04/18 2011/04/19 2011/04/20 2011/04/21 2011/04/22 2011/04/23 2011/04/24 2011/04/25 2011/04/26 2011/04/27 2011/04/28 2011/04/29 2011/04/30
2011/05/01 2011/05/02 2011/05/03 2011/05/04 2011/05/05 2011/05/06 2011/05/07

### Browse by creation date

66 72 73 75 79 85 86 87 88 89 90 91 92 93 96 97 00 01 02 03 04 05 06 07 08 09 10
1966/12
1972/02 1972/08
1973/04
1975/03
1979/08
1985/03 1985/06
1986/05
1987/06
1988/01
1989/12
1990/01 1990/07 1990/08 1990/10
1991/05
1992/01 1992/06 1992/12
1993/10
1996/11
1997/12
2000/05 2000/06 2000/09 2000/11
2001/02 2001/03 2001/06 2001/07 2001/09 2001/10 2001/11
2002/01 2002/02 2002/03 2002/04 2002/07 2002/08 2002/09 2002/11
2003/01 2003/02 2003/03 2003/04 2003/05 2003/06 2003/07 2003/08 2003/09 2003/10 2003/11 2003/12
2004/01 2004/02 2004/03 2004/04 2004/05 2004/06 2004/07 2004/08 2004/09 2004/10 2004/11 2004/12
2005/01 2005/02 2005/03 2005/04 2005/05 2005/06 2005/07 2005/08 2005/09 2005/10 2005/11 2005/12
2006/01 2006/02 2006/03 2006/04 2006/05 2006/06 2006/07 2006/08 2006/09 2006/10 2006/11 2006/12
2007/01 2007/02 2007/03 2007/04 2007/05 2007/06 2007/07 2007/08 2007/09 2007/10 2007/11 2007/12
2008/01 2008/02 2008/03 2008/04 2008/05 2008/06 2008/07 2008/08 2008/09 2008/10 2008/11 2008/12
2009/01 2009/02 2009/03 2009/04 2009/05 2009/06 2009/07 2009/08 2009/09 2009/10 2009/11 2009/12
2010/01 2010/02

### Browse by origin

A B C D F G H I J K L M N O P Q R S T U V W Y Z
Embassy Athens Embassy Asuncion Embassy Astana Embassy Asmara Embassy Ashgabat Embassy Apia Embassy Ankara Embassy Amman Embassy Algiers Embassy Addis Ababa Embassy Accra Embassy Abuja Embassy Abu Dhabi Embassy Abidjan Consulate Auckland Consulate Amsterdam Consulate Adana American Institute Taiwan, Taipei
Embassy Bujumbura Embassy Buenos Aires Embassy Budapest Embassy Bucharest Embassy Brussels Embassy Bridgetown Embassy Bratislava Embassy Brasilia Embassy Bogota Embassy Bishkek Embassy Bern Embassy Berlin Embassy Belmopan Embassy Belgrade Embassy Beirut Embassy Beijing Embassy Banjul Embassy Bangkok Embassy Bandar Seri Begawan Embassy Bamako Embassy Baku Embassy Baghdad Consulate Barcelona
Embassy Copenhagen Embassy Conakry Embassy Colombo Embassy Chisinau Embassy Caracas Embassy Canberra Embassy Cairo Consulate Curacao Consulate Ciudad Juarez Consulate Chennai Consulate Casablanca Consulate Cape Town Consulate Calgary
Embassy Dushanbe Embassy Dublin Embassy Doha Embassy Djibouti Embassy Dili Embassy Dhaka Embassy Dar Es Salaam Embassy Damascus Embassy Dakar Consulate Dubai
Embassy Freetown Consulate Fukuoka
Embassy Guatemala Embassy Gaborone Consulate Guayaquil Consulate Guadalajara
Embassy Helsinki Embassy Harare Embassy Hanoi Consulate Ho Chi Minh City Consulate Hermosillo Consulate Hamilton Consulate Hamburg Consulate Halifax
Iran RPO Dubai Embassy Islamabad Consulate Istanbul
Embassy Jakarta Consulate Jerusalem Consulate Jeddah
Embassy Kyiv Embassy Kuwait Embassy Kuala Lumpur Embassy Kinshasa Embassy Kingston Embassy Kigali Embassy Khartoum Embassy Kathmandu Embassy Kampala Embassy Kabul Consulate Kolkata
Embassy Luxembourg Embassy Luanda Embassy London Embassy Ljubljana Embassy Lisbon Embassy Lima Embassy Lilongwe Embassy La Paz Consulate Lahore Consulate Lagos
Mission USOSCE Mission USNATO Mission UNESCO Embassy Muscat Embassy Moscow Embassy Montevideo Embassy Monrovia Embassy Minsk Embassy Mexico Embassy Mbabane Embassy Maputo Embassy Manila Embassy Manama Embassy Managua Embassy Malabo Embassy Madrid Consulate Munich Consulate Mumbai Consulate Montreal Consulate Monterrey Consulate Milan Consulate Melbourne
Embassy Nicosia Embassy Niamey Embassy New Delhi Embassy Ndjamena Embassy Nassau Embassy Nairobi Consulate Naples Consulate Naha
Embassy Ouagadougou Embassy Ottawa Embassy Oslo
Embassy Pristina Embassy Pretoria Embassy Prague Embassy Port Of Spain Embassy Port Louis Embassy Port Au Prince Embassy Phnom Penh Embassy Paris Embassy Paramaribo Embassy Panama Consulate Peshawar
Embassy Quito Consulate Quebec
REO Basrah Embassy Rome Embassy Riyadh Embassy Riga Embassy Reykjavik Embassy Rangoon Embassy Rabat Consulate Rio De Janeiro Consulate Recife
Secretary of State Embassy Suva Embassy Stockholm Embassy Sofia Embassy Skopje Embassy Singapore Embassy Seoul Embassy Sarajevo Embassy Santo Domingo Embassy Santiago Embassy Sanaa Embassy San Salvador Embassy San Jose Consulate Strasbourg Consulate St Petersburg Consulate Shenyang Consulate Shanghai Consulate Sapporo Consulate Sao Paulo
Embassy Tunis Embassy Tripoli Embassy Tokyo Embassy The Hague Embassy Tel Aviv Embassy Tehran Embassy Tegucigalpa Embassy Tbilisi Embassy Tashkent Embassy Tallinn Consulate Toronto Consulate Tijuana
USUN New York USEU Brussels US Office Almaty US Mission Geneva US Interests Section Havana US Delegation, Secretary UNVIE Embassy Ulaanbaatar
Embassy Vilnius Embassy Vienna Embassy Vatican Embassy Valletta Consulate Vladivostok Consulate Vancouver
Embassy Windhoek Embassy Wellington Embassy Warsaw
Embassy Yerevan Embassy Yaounde
Embassy Zagreb

### Browse by tag

A B C D E F G H I J K L M N O P Q R S T U V W X Y Z
ASEC AF AFIN AM AJ AG AS AEMR AMGT AORC APER AU ACBAQ AFGHANISTAN AR AE ADANA ADPM APECO AMED AX AL ADCO AA AECL AADP AMEX ACAO ANET AODE ASCH AY APEC AID AORG ASEAN ABUD AGAO AFSI AFSN AINF AGR AROC AO AFFAIRS ASIG ABLD ASUP AND ARM AQ ATFN AC ATRN ACOA AMBASSADOR AUC ASEX ARF APCS AER AVERY AGRICULTURE AMG AORL AGMT ALOW AFU ASECKFRDCVISKIRFPHUMSMIGEG AZ AN AMCHAMS AIT ADM ACABQ ACS
BR BK BA BRUSSELS BEXP BM BD BL BO BU BILAT BN BT BX BTIO BIDEN BG BE BP BY BBSR BC BTIU BWC BB BF BH BMGT
CO CASC CS CA CONDOLEEZZA CE CVIS CU CPAS CMGT COUNTER CH COUNTRY CJAN CG CIDA CJUS CI CY CD CDG CBSA CEUDA CR CM CLMT CAC CBW CODEL COPUOS CIC CW CBE CHR CFED CT CONS CWC CIA CTM CDC CVR CF CLINTON COUNTERTERRORISM CITEL CLEARANCE COE CN CACS CAN CB CSW CITT CARSON CACM CDB COM CROS CV CAPC CKGR CBC CTR CNARC CARICOM CL CICTE CIS
DR DHS DA DJ DEA DPRK DEPT DOMESTIC DOE DS DE DEFENSE DO DAO DCM DEAX DK DTRA DISENGAGEMENT DOD
EINV ETRD ECON EPET ENRG EAGR EC EFIN EAID ELTN EIND ELAB EAIR ECIN EUN EG EU ETTC ET EI EWWT EFIS EMIN ER EPA ENVI ENGR ETRC EXTERNAL ECPS EN ELN EINT ETRDEINVTINTCS ES EZ ETRO ETRDEINVECINPGOVCS EDU ETRN EFTA EAIG EK EUREM ECONCS ECONOMICS ENVR ELECTIONS EAP ENIV ECONOMY ESA EINN ECONOMIC EIAR EXBS ECA ECUN EINDETRD EUR EREL EUC ESENV ECONEFIN ECIP ENERG EFIM EAIDS ETRDECONWTOCS EUNCH EINVETC EURN EINVEFIN ETC ENGY EINVECONSENVCSJA EUMEM ETRA ERD ENNP ECINECONCS EFINECONCS EEPET EXIM ERNG
FR FREEDOM FTA FJ FARC FI FTAA FAC FBI FOREIGN FOI FM FAO FAS FINR FDA FOR FINANCE FMLN FO FISO
GTMO GG GM GV GOV GOI GL GAERC GH GA GY GT GR GF GCC GE GZ GTIP GERARD GLOBAL GANGS GAZA
HO HA HR HUMAN HK HU HILLARY HI HSTC HURI HYMPSK HUMOR HEBRON
IR IAEA IS IZ IN IT IO IAHRC ID IC IRAQI IWC ISLAMISTS IV ICAO INDO ITPHUM ITPGOV ITALIAN IPR ICRC INTERPOL IQ IBET IMO INR INTERNAL ICJ ICTY IRS ILO INRA INRO ISRAELI IEA INRB ITALY IL ITU ITRA IBRD IIP ILC IZPREL IMF IRAJ IA IDP ITF IF INMARSAT INTELSAT IGAD ISRAEL ICTR IEFIN IRC IACI IDA
JA JO JUS JP JOSEPH JM JAMES JOHNNIE JOHN
KS KN KTFN KTDB KTIP KIRF KPAO KDEM KCOR KE KMPI KSCA KZ KG KNUP KNNP KPAL KCRM KIPR KPKO KFLO KSEP KOMC KISL KNNPMNUC KWBG KFRD KUNR KWMN KSTC KFLU KOLY KMDR KJUS KSTH KAWC KU KWAC KNPP KERG KSEO KACT KHLS KGHG KFRDCVISCMGTCASCKOCIASECPHUMSMIGEG KCRCM KDRG KTIA KVPR KV KIDE KICC KPRP KBIO KSUM KGIT KCFE KBTS KCIP KGIC KPAI KTLA KTEX KFSC KPLS KHIV KCSY KSAC KTRD KID KMRS KOM KSAF KRVC KR KMOC KNAR KHDP KSPR KFIN KBTR KOCI KJUST KNEI KAWK KGCC KMCA KBCT KREL KMFO KFRDKIRFCVISCMGTKOCIASECPHUMSMIGEG KFTFN KVRP KIRC KCOM KO KLIG KAID KNSD KHUM KSEC KRAD KCMR KPWR KCHG KICA KPIN KESS KDEV KCGC KWWMN KPRV KPAK KWNM KWMNCS KRFD KVIR KSCI KPOA KDDG KWMM KCFC KTER KREC KIFR KCRS KHSA KRGY KMIG KTBT KOMS KX KRCM KRIM KPAONZ KNUC KDEMAF
LE LY LG LH LI LTTE LAB LOG LA LT LO LU LABOR
MP MY MOPS MCAP MARR MNUC MUCN MTCRE MASS MAPP MIL MX MEDIA MO MPOS MU ML MA MERCOSUR MG MD MW MK MAS MT MI MOPPS MASC MR MTS MLS MILI MAR MTRE MEPN MTCR MEPI MQADHAFI MAPS MARAD MEETINGS MEPP MZ MILITARY MDC MC MV MCC MRCRE MASSMNUC MIK
NU NZ NATO NPT NL NI NAFTA NDP NIPP NP NPA NG NRR NO NEW NE NH NR NA NS NSF NZUS NATIONAL NSG NC NT NAR NK NV NORAD NASA NSSP NW NATOPREL NPG NGO NSC NSFO
OVIP OPIC OEXC OTRA OPDC OREP OAS OPRC OIIP OSCE OFFICIALS OMIG ODIP OFDP OECD OBSP OPCW OTR OSAC OSCI ON OCII OES OVP OPAD OFDA OIE OIC OHUM OCS
PGOV PINR PREL PHSA PTER PE PREF PHUM PK PARM PINS PM PL PO PA PBTS PBIO POL PARMS PROG PAK POLITICS PORG PTBS PNAT PUNE POLICY PDOV PCI PGOVSMIGKCRMKWMNPHUMCVISKFRDCA PBT PP PS PG PY PTERE PGOF PALESTINIAN PKFK PSOE PEPR PPA PINT PMAR PRELP PSEPC PREFA PGOVE PINF PNG PMIL PGOC PFOR PCUL PLN PROP PAO POLINT PGGV PHALANAGE PARTY PGOVLO PHUS PDEM PECON PROV PAS PHUMPREL PGIV PRAM PF PRL PHUH PHUMBA POV PSA PHUMPGOV POGOV PEL PNR PREO PAHO PSI PINL PU PRGOV PAIGH POLITICAL PARTIES POSTS
QA
RS RCMP RICE RU REACTION REPORT REGION RIGHTS RO RW RF RM RFE RSP RP RIGHTSPOLMIL ROBERT ROOD RELATIONS RUPREL RSO
SOCI SN SY SNAR SENV SP SZ SCUL SA SO SW SMIG SU SENVKGHG SR SYRIA SF SI SC SWE SARS STEINBERG SG SIPRS ST SL SPCE SNARIZ SSA SK SPCVIS SOFA SEVN SIPDIS SAN SYR SHUM SANC SNARCS SAARC SNARN SHI SH SEN SCRS
TU TPHY TI TX TSPL TRGY TBIO TF TERRORISM TH TIP TC TO TSPA TW TZ TNGD TT TL TV TS TRSY TINT TN TURKEY TBID TD TP TAGS TFIN TK TR THPY
UK UNSC USTR UG UNGA UZ USEU US UN UNC USUN UP UY UNESCO USPS UNHRC UNO UNHCR UNCHR USAID UNVIE UAE UNMIK USOAS UNFICYP UV UNEP UNODC UNCHS UNIDROIT UNDESCO UNCHC UNDP UNAUS USNC UNCSD UNCND UNICEF UNDC UNPUOS UE
VT VZ VE VTEG VTPREL VM VI VTIZ VAT VN VC
WS WTO WTRO WTRQ WI WZ WHO WFP WWARD WHA WB WBG WIPO WITH WMO WEU WHTI WMD WA
XA XF XM XL XW XV XR XB XU XY XH XG XE XK XX XD XI XT XS XC XZ XTAG XQ
YE YM YI YMCS
ZI ZO ZU ZEALAND ZK ZR ZF ZP ZN ZA ZB ZOELLICK ZL ZANU ZJ

### Browse by classification

CONFIDENTIAL CONFIDENTIAL//NOFORN SECRET SECRET//NOFORN UNCLASSIFIED UNCLASSIFIED//FOR OFFICIAL USE ONLY

### Community resources

Follow us on Twitter Check our Reddit Twitter this Digg this page Contact us on IRC

courage is contagious

### Viewing cable 06OTTAWA2021, POTENTIAL FOR IPR PROGRESS: CANADA'S PROPOSED

If you are new to these pages, please read an introduction on the structure of a cable as well as how to discuss them with others. See also the FAQs
Understanding cables
Every cable message consists of three parts:

- The top box shows each cables unique reference number, when and by whom it originally was sent, and what its initial classification was.
- The middle box contains the header information that is associated with the cable. It includes information about the receiver(s) as well as a general subject.
- The bottom box presents the body of the cable. The opening can contain a more specific subject, references to other cables (browse by origin to find them) or additional comment. This is followed by the main contents of the cable: a summary, a collection of specific topics and a comment section.

To understand the justification used for the classification of each cable, please use this WikiSource article as reference.
Discussing cables
If you find meaningful or important information in a cable, please link directly to its unique reference number. Linking to a specific paragraph in the body of a cable is also possible by copying the appropriate link (to be found at theparagraph symbol). Please mark messages for social networking services like Twitter with the hash tags #cablegate and a hash containing the reference ID e.g. #06OTTAWA2021.

Reference ID | Created | Released | Classification | Origin
--- | --- | --- | --- | ---
06OTTAWA2021 | 2006-06-29 19:57 | 2011-04-28 00:00 | UNCLASSIFIED//FOR OFFICIAL USE ONLY | Embassy Ottawa

`

    VZCZCXRO5122
    RR RUEHGA RUEHHA RUEHQU RUEHVC
    DE RUEHOT #2021/01 1801957
    ZNR UUUUU ZZH
    R 291957Z JUN 06
    FM AMEMBASSY OTTAWA
    TO RUEHC/SECSTATE WASHDC 3024
    INFO RUCNCAN/ALL CANADIAN POSTS COLLECTIVE
    RUCPDOC/DEPT OF COMMERCE WASHDC

` `

    UNCLAS SECTION 01 OF 02 OTTAWA 002021

    SIPDIS

    SENSITIVE
    SIPDIS

    STATE PASS TO USTR FOR GARDE, ESPINEL, CHANDLER
    STATE PASS TO USDOC FOR GWORD, JBOGER
    STATE PASS TO USPTO FOR MKEPLINGER

    E.O. 12958: N/A
    TAGS: KIPR ECON TBIO CA
    SUBJECT: POTENTIAL FOR IPR PROGRESS:  CANADA'S PROPOSED
    DATA PROTECTION REGULATIONS

    REF: A. OTTAWA 1701

         ¶B. OTTAWA 1317

    ¶1.  (SBU)  Summary:  The GOC has proposed a two-regulation
    package (significantly different from its 2004 proposal)
    consisting of data protection for the innovative
    pharmaceutical industries and "Patented Medicines (Notice of
    Compliance)" for the generic drug industries, a combination
    designed to force compromise between the two sectors.
    Although the innovative pharmaceutical industry organizations
    PhRMA and Rx&D have minor complaints which they hope to have
    addressed in the final regulations (the comment period ends
    July 17), in general the package seems to be a positive
    development for IPR protection in Canada.  In particular, the
    Data Protection regulation is designed to bring Canada into
    compliance with its international obligations to provide
    protection for proprietary data belonging to patent-holding
    companies, something that the Embassy has been encouraging.
    Assuming the proposed rules are finalized, industry observes
    believe that this will be a step forward for Canada's
    protection of IPR and will directly address one complaint
    from the last two Special 301 Reports on Canada.  End Summary.

    The Regulations
    ---------------

    ¶2.  (U)  (SBU)  The Patented Medicines (Notice of Compliance)
    or PMNOC regulation and, to a lesser extent, the Data
    Protection regulation are complex, and we would welcome
    insights from USG experts.  The data protection regulation
    can be found at
    canadagazette.gc.ca/partI/2006/20060617/html/ regle4-e.html
    The PMNOC regulation can be found at
    canadagazette.gc.ca/partI/2006/20060617/html/ regle6-e.html
    Our initial perusal and conversations with contacts have
    provided the following information.

    ¶3.  (SBU) The draft Data Protection regulation stipulates
    that a secondary manufacturer (usually a generic) cannot file
    a new drug submission on the basis of a direct or indirect
    comparison between the new drug and an innovative drug until
    six years after the first notice of compliance was issued to
    the innovator.  The submission will not be approved until at
    least eight years after the first notice of compliance was
    issued.  This data protection period of eight years compares
    favorably to the U.S. "five plus three" period.  (Comment:
    One observer joked to us that now Canada would have better
    data protection than the United States and that the
    innovative industry may start to use this as leverage to
    argue for better data protection in the United States.  End
    comment.)  Both the Canadian industry group Rx&D and PhRMA in
    the United States are preparing comments to submit to Health
    Canada.  From discussions with industry contacts, we believe
    the industry comments will focus on requests for
    clarification, particularly surrounding the transitional
    language that will determine how drug submissions already in
    the pipeline are treated.  A particular point which seems
    unclear to many observers (and of concern to the
    pharmaceutical industry) is paragraph (5) which states that
    the eight year protection period does not apply "if the
    innovative drug is not being marketed in Canada."  We expect
    that the final regulations will clarify how this will be
    applied.  However, the innovative industry's reaction to the
    data protection regulation is positive, with observers
    stating that this will not only bring Canada into compliance
    with its international obligations but will also make the
    country more competitive internationally.
    Qcountry more competitive internationally.

    ¶4.  (SBU)  The Patented Medicines (Notice of Compliance) or
    PMNOC regulation is the part of the package designed to keep
    the generic companies in the deal.  The PMNOC regulation is
    more complex than the data protection regulation, but in
    general it is intended to limit innovative drug companies'
    ability to "evergreen" drug patents, or renew patents based
    on small changes to a drug.  The PMNOC regulation attempts to
    address the unintended consequences of unclear language in
    previous regulation which required court interpretation;
    these include the "possibility that an innovator company may
    delay generic market entry by listing new and sometimes
    irrelevant patents on the basis of minor product revisions."
    In what seems to be a valuable victory for the innovative
    drug industry, however, the PMNOC's Regulatory Impact
    Assessment Statement states that dosage form patents (patents
    that focus on the form of the drug, not its chemical
    composition) deserve "special protection provided by the
    PM(NOC) regulations," adding that this is "particularly true

    OTTAWA 00002021  002 OF 002

    in the case of biologic drugs where effective administration
    of the medicinal ingredient is often dependent on the
    development of new and innovative delivery mechanisms."  The
    generic industry in Canada has not made any public statement
    on the draft regulations, although they will probably submit
    formal comments.  Our contacts also tell us that the generics
    are trying to arrange for meetings with relevant officials
    and members of parliament before the comment period ends on
    July 17.

    GOC Officials' Perspective
    ---------------------------

    ¶5.  (SBU) Our GOC contacts seem confident that these
    regulations will be finalized, with very few changes, in as
    short a period as is possible under Canada's regulatory
    process.  They describe the regulations as fair and balanced,
    and they suggest that neither the innovative nor the generic
    industry should be surprised by the regulations' content.  In
    general, this is what we are hearing from industry contacts
    as well, although industry contacts hesitate to describe
    themselves as happy with the regulations and insist that
    certain changes need to be made.  Any rhetoric about pushing
    for 10 years of data protection such as in Europe seems to be
    more a bargaining tool than an actual goal.  GOC officials
    are aware that both industries, but particularly the
    innovative industry, are eager for a package to be finalized
    and are willing to accept the compromises inherent in these
    proposed regulations.

    Domestic Political Context
    --------------------------

    ¶6.  (SBU) The current Conservative government has been more
    receptive to U.S. concerns about intellectual property
    rights, and domestically the Conservative party is less
    beholden to the generic industry, which is predominantly
    based in the greater Toronto area, a Liberal stronghold.
    (Comment:  a recent bit of much-hyped campaign scandal
    involved questionable donations to a Toronto-area Liberal
    MP--totalling C$54,000--from Apotex Inc's top two executives,
    their wives and six children.  Apotex is Canada's largest
    generic drug company.  End comment.)  The innovative drug
    companies, on the other hand, are primarily based in Quebec,
    where the Conservatives are very interested in picking up
    additional seats.  In general, this suggests that the
    generics industry, which is thought to be responsible for
    delaying progress on the 2004 proposal of the first version
    of these regulations, will not be able to delay progress on
    the new draft regulations.  The most optimistic timeframe for
    final regulations is probably the end of 2006.  As with our
    other IPR goal of amendments to the copyright act, much will
    hinge on whether another election is called in the meantime.
    An election before finalization of the regulations would at
    the very least delay them regulations and could result in yet
    another redraft.

    Visit Canada's Classified Web Site at
    http://www.state.sgov.gov/p/wha/ottawa

    WILKINS

`